查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1159232

失智症治療藥的全球市場:預測(2022年～2028年)

Dementia Drugs Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 127 Pages | 商品交期: 2-3個工作天內

價格

全球失智症治療藥的市場規模在預測期間內預計將以約8.1％的年複合成長率擴大。目標疾病患病率的增加、新技術和藥物的引入、政府資金的增加和癡呆症意識計劃的增加都在推動市場的增長。

本報告提供全球失智症治療藥市場相關調查，提供市場概要，以及各失智症類型，各藥物類型，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

第3章 競爭情形

  • Pfizer Inc
  • Teva Pharmaceuticals Industries Ltd
  • Merck & Co Inc
  • GlaxoSmithKline Plc
  • Cadila Healthcare Ltd
  • 主要策略分析
  • COVID-19對主要加入企業帶來的影響

第4章 市場區隔

  • 全球失智症治療藥市場，各失智症類型
    • 路易氏體失智症
    • 帕金森氏症失智症
    • 阿茲海默症失智症
    • 其他
  • 全球失智症治療藥市場，各藥物類型
    • 膽鹼酯□抑制劑
    • MAO抑制劑
    • 麩胺酸抑制劑
    • 其他

第5章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 企業簡介

  • Abbvie Inc
  • ACADIA Pharmaceutical Inc
  • Apotex Corp
  • Aurobindo Pharma Ltd
  • Biogen Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc
  • Merck & Co Inc
  • Mylan Nv
  • Novartis International AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
Product Code: OMR2026337

Global Dementia Drugs Market Size, Share & Trends Analysis Report By Type of Dementia (Lewy Body Dementia, Parkinson's Disease, Alzheimer's Disease, and Others), By Type of Drug (Cholinesterase Inhibitors, MAO Inhibitors, Glutamate Inhibitors, and Others), and Forecast 2022-2028

The global dementia drugs market is anticipated to grow at a significant CAGR of around 8.1% during the forecast period. The global dementia drugs market is largely driven due to the increasing prevalence of target diseases, the introduction of new and innovative technologies and drugs, and increased government funding and awareness programs for dementia. The growing senior population suffering from various disorders is also the major factor that is playing a substantial role in the market. However, the low awareness regarding the dementia condition in developing regions turns out to be a restraint for the growth of the dementia drugs market. Additionally, the low diagnosis rate will also hamper the growth of the dementia drug market during the forecast period. Moreover, the side effects of dementia drugs such as nausea, vomiting, loss of appetite, sleep problems, feeling of tiredness will lower the popularity of these drugs in the dementia drug market. For instance, in Aug 2021, the National Institutes of Health (NIH) awarded Tabula Rasa HealthCare (TRHC) a healthcare technology company advancing the safe use of medications.

The global dementia drugs market is segmented based on the type of dementia and type of drugs. Based on the type of dementia, the market is sub-segmented into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease dementia, and others such as vascular dementia. Further based on the type of drugs, the market is sub-segmented into cholinesterase inhibitors, MAO inhibitors, Glutamate inhibitors, and others. The above-mentioned segments can be customized as per the requirements. For instance, in Feb 2019, Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd and Evotec together joined The Dementia Consortium.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in dementia drugs during the forecast period. The growth of the region is owing to the well-developed healthcare structure in the region. Additionally, the increasing number of patients diagnosed with dementia as well as its associated condition such as Parkinson's disease will also fuel the dementia drugs market growth across the region.

Some of the key players operating in the global dementia drugs market include Teva Pharmaceuticals Industries Ltd., Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline Plc, Aurobindo Pharma Ltd., Biogen Inc., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launches, mergers, and acquisitions, collaborations with the government, and new drug commercialization to stay competitive in the market. For instance, in June 2021, Aducanumab (Aduhelm) was licensed by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease.

Research Methodology

The market study of the Global dementia drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Dementia Drugs Market by Dementia Type

2. Global Dementia Drugs Market by Drug Type

The Report Covers:

  • Comprehensive Research Methodology of the Global Dementia Drugs Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the market Global Dementia Drugs Market.
  • Insights about market determinants that are stimulating the Global Dementia Drugs Market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Dementia Drugs Market
  • 1.1. Recovery Scenario of Global Dementia Drugs Market
  • 1.2. Research Methods and Tools
  • 1.3. Market Breakdown
    • 1.3.1. By Segments
    • 1.3.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Pfizer Inc
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Teva Pharmaceuticals Industries Ltd
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Merck & Co Inc
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. GlaxoSmithKline Plc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Cadila Healthcare Ltd
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

Global Dementia Drugs Market by Dementia Type

    • 4.1.1. Lewy Body Dementia
    • 4.1.2. Parkison's Disease Dementia
    • 4.1.3. Alzheimer's Disease Dementia
    • 4.1.4. Others

Global Dementia Drugs Market by Drugs Type

    • 4.1.5. Cholinesterase Inhibitors
    • 4.1.6. MAO Inhibitors
    • 4.1.7. GlutamateInhibitors
    • 4.1.8. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

5.4.1 Latin America

5.4.2 Middle East and Africa

6. Company Profiles

  • 6.1. Abbvie Inc
  • 6.2. ACADIA Pharmaceutical Inc
  • 6.3. Apotex Corp
  • 6.4. Aurobindo Pharma Ltd
  • 6.5. Biogen Inc
  • 6.6. GlaxoSmithKline Plc
  • 6.7. Johnson & Johnson Services, Inc
  • 6.8. Merck & Co Inc
  • 6.9. Mylan Nv
  • 6.10. Novartis International AG
  • 6.11. Pfizer Inc
  • 6.12. Teva Pharmaceutical Industries Ltd

LIST OF TABLES

  • 1. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY DEMENTIA TYPE OF DEMENTIA, 2021-2028 ($ MILLION)
  • 2. GLOBAL LEWY BODY DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL PARKINSONS DISEASE DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ALZHEIMERS DISEASE DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL OTHERS DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
  • 7. GLOBAL CHOLINESTERASE INHIBITORS IN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL MAO INHIBITORS IN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL GLUTAMATE INHIBITORS IN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL OTHERS DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUG 2021-2028 ($ MILLION)
  • 15. EUROPEAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2021-2028 ($ MILLION)
  • 17. EUROPEAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUG, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUG, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUG, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL DEMENTIA DRUG MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL DEMENTIA DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL DEMENTIA DRUGS MARKET, 2021-2028 (%)
  • 4. GLOBAL DEMENTIA DRUGS MARKET SHARE BY DEMANTIA TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL LEWY BODY DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL PARKINSONS DISEASE DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 7. GLOBAL ALZHEIMERS DISEASE DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL OTHERS DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021 VS 2028 (%)
  • 10. GLOBAL CHOLINESTERASE INHIBITORS DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL MAO INHIBITORS DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL GLUTAMATE INHIBITORS DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL OTHERS DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL DEMENTIA DRUGS MARKET SHARE BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 15. US DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD DEMENTIA DRUGS MARKET SIZE, 2021-2028 ($ MILLION)